The following table shows contents overview and links.
| Pharmaceutical patent practice | Links |
|---|---|
| <Article> How to Rewrite Method-of-Treatment Claims | Click |
| <Article> Recently Granted Epitope-Based Antibody Patents | Click |
| <Article> ‘Antibody Derivative’ and ‘Bispecific Antibody’ Described in Dependent Claims or Specification | Click |
| How to write claims regarding methods of treating a disease | Click |
| The limitation of "for use in..." in typical European medical use claims does not contribute to patentability | Click |
| Invalidation trials against Ono’s anti-PD-1 antibody patents and anti-PD-L1 antibody patents were filed in Japan | Click |
| History of Avastin (anti-VEGF antibody)-related patents and biosimilar approval | Click |
| Circumstances of Amgen's Repatha (anti-PCSK9 antibody)-related patents | Click |
| List of invalidation trials and oppositions against Biopharmaceutical patents filed between May 2017 and May 2019 | Click |
| Examination Handbook for Medicinal Inventions | Click |
| Examination Handbook for Biological Inventions | Click |
| Patent Law regarding patent term extension in the pharmaceutical field | Click |
| List of patent term extension applications and drugs (on or before 2000) | Click |
| List of patent term extension applications and drugs (2001-2005) | Click |
| List of patent term extension applications and drugs (2006-2010) | Click |
| List of patent term extension applications and drugs (2011-2015) | Click |
| List of patent term extension applications and drugs (2016-2019) | Click |
